ScholarWorks@Korea University

Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)

Full metadata record
DC Field Value Language
dc.contributor.authorSim, Sung Hoon-
dc.contributor.authorKim, Jeong Eun-
dc.contributor.authorKim, Min Hwan-
dc.contributor.authorPark, Yeon Hee-
dc.contributor.authorKim, Jee Hyun-
dc.contributor.authorSuh, Koung Jin-
dc.contributor.authorKoh, Su-Jin-
dc.contributor.authorPark, Kyong Hwa-
dc.contributor.authorKang, Myoung Joo-
dc.contributor.authorAhn, Mi Sun-
dc.contributor.authorLee, Kyoung Eun-
dc.contributor.authorKim, Hee -Jun-
dc.contributor.authorAhn, Hee Kyung-
dc.contributor.authorKim, Han Jo-
dc.contributor.authorPark, Keon Uk-
dc.contributor.authorByun, Jae Ho-
dc.contributor.authorPark, Jin Hyun-
dc.contributor.authorLee, Gyeong-Won-
dc.contributor.authorLee, Keun Seok-
dc.contributor.authorSohn, Joohyuk-
dc.contributor.authorJung, Kyung Hae-
dc.contributor.authorPark, In Hae-
dc.date.accessioned2022-10-06T05:00:50Z-
dc.date.available2022-10-06T05:00:50Z-
dc.date.created2022-10-06-
dc.date.issued2022-10-
dc.identifier.issn0960-9776-
dc.identifier.urihttps://scholar.korea.ac.kr/handle/2021.sw.korea/144075-
dc.description.abstractWe investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma (R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.-
dc.languageEnglish-
dc.language.isoen-
dc.publisherCHURCHILL LIVINGSTONE-
dc.subjectDOUBLE-BLIND-
dc.subjectPROGRESSION-
dc.subjectRETREATMENT-
dc.subjectGUIDELINE-
dc.subjectMUTATIONS-
dc.subjectEMTANSINE-
dc.subjectLAPATINIB-
dc.subjectHER2-
dc.titlePhase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)-
dc.typeArticle-
dc.contributor.affiliatedAuthorPark, In Hae-
dc.identifier.doi10.1016/j.breast.2022.08.002-
dc.identifier.scopusid2-s2.0-85136302494-
dc.identifier.wosid000854087700004-
dc.identifier.bibliographicCitationBREAST, v.65, pp.172 - 178-
dc.relation.isPartOfBREAST-
dc.citation.titleBREAST-
dc.citation.volume65-
dc.citation.startPage172-
dc.citation.endPage178-
dc.type.rimsART-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaOncology-
dc.relation.journalResearchAreaObstetrics & Gynecology-
dc.relation.journalWebOfScienceCategoryOncology-
dc.relation.journalWebOfScienceCategoryObstetrics & Gynecology-
dc.subject.keywordPlusDOUBLE-BLIND-
dc.subject.keywordPlusEMTANSINE-
dc.subject.keywordPlusGUIDELINE-
dc.subject.keywordPlusHER2-
dc.subject.keywordPlusLAPATINIB-
dc.subject.keywordPlusMUTATIONS-
dc.subject.keywordPlusPROGRESSION-
dc.subject.keywordPlusRETREATMENT-
dc.subject.keywordAuthorClinical trial-
dc.subject.keywordAuthorHER2 positive-
dc.subject.keywordAuthorMetastatic breast cancer-
dc.subject.keywordAuthorTrastuzumab biosimilar-
dc.subject.keywordAuthorctDNA-
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles
Show simple item record

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

STATISTICS
Total View :7,088,512
Today View :20,531

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

COPYRIGHT © 2021 Korea University. All Rights Reserved.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어